Market Closed -
Japan Exchange
11:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
354
JPY
|
+5.04%
|
|
+56.64%
|
+30.63%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
4,939
|
5,273
|
7,641
|
6,623
|
3,776
|
3,268
|
Enterprise Value (EV)
1 |
3,883
|
3,923
|
6,584
|
5,558
|
2,476
|
2,497
|
P/E ratio
|
-3.46
x
|
-4.95
x
|
59.3
x
|
-7.74
x
|
-4.47
x
|
-3.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
49.4
x
|
62
x
|
7.45
x
|
24.1
x
|
19
x
|
20.3
x
|
EV / Revenue
|
38.8
x
|
46.2
x
|
6.42
x
|
20.2
x
|
12.4
x
|
15.5
x
|
EV / EBITDA
|
-2.76
x
|
-3.85
x
|
45.7
x
|
-7.16
x
|
-3.49
x
|
-2.89
x
|
EV / FCF
|
-3.16
x
|
-8.96
x
|
-18.3
x
|
-19
x
|
-5.86
x
|
-4.3
x
|
FCF Yield
|
-31.6%
|
-11.2%
|
-5.46%
|
-5.26%
|
-17.1%
|
-23.3%
|
Price to Book
|
4.25
x
|
4.2
x
|
5.42
x
|
4.97
x
|
2.59
x
|
3.18
x
|
Nbr of stocks (in thousands)
|
9,214
|
11,414
|
11,439
|
12,860
|
15,287
|
17,759
|
Reference price
2 |
536.0
|
462.0
|
668.0
|
515.0
|
247.0
|
184.0
|
Announcement Date
|
30/03/17
|
30/03/18
|
29/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
1 |
100
|
85
|
1,026
|
275
|
199
|
161
|
EBITDA
1 |
-1,406
|
-1,020
|
144
|
-776
|
-710
|
-863
|
EBIT
1 |
-1,414
|
-1,024
|
140
|
-781
|
-719
|
-865
|
Operating Margin
|
-1,414%
|
-1,204.71%
|
13.65%
|
-284%
|
-361.31%
|
-537.27%
|
Earnings before Tax (EBT)
1 |
-1,415
|
-964
|
139
|
-782
|
-780
|
-911
|
Net income
1 |
-1,414
|
-966
|
129
|
-782
|
-783
|
-914
|
Net margin
|
-1,414%
|
-1,136.47%
|
12.57%
|
-284.36%
|
-393.47%
|
-567.7%
|
EPS
2 |
-154.9
|
-93.25
|
11.27
|
-66.56
|
-55.25
|
-53.15
|
Free Cash Flow
1 |
-1,229
|
-438
|
-359.5
|
-292.1
|
-422.4
|
-580.6
|
FCF margin
|
-1,228.75%
|
-515.29%
|
-35.04%
|
-106.23%
|
-212.25%
|
-360.64%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/17
|
30/03/18
|
29/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,056
|
1,350
|
1,057
|
1,065
|
1,300
|
771
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,229
|
-438
|
-360
|
-292
|
-422
|
-581
|
ROE (net income / shareholders' equity)
|
-79.6%
|
-79.8%
|
9.67%
|
-56.7%
|
-54.6%
|
-71.7%
|
ROA (Net income/ Total Assets)
|
-46.1%
|
-44.1%
|
5.56%
|
-32.1%
|
-27.6%
|
-33.8%
|
Assets
1 |
3,066
|
2,192
|
2,320
|
2,437
|
2,842
|
2,703
|
Book Value Per Share
2 |
126.0
|
110.0
|
123.0
|
104.0
|
95.30
|
57.80
|
Cash Flow per Share
2 |
115.0
|
118.0
|
92.20
|
82.00
|
91.20
|
52.40
|
Capex
1 |
343
|
5
|
1
|
13
|
7
|
91
|
Capex / Sales
|
343%
|
5.88%
|
0.1%
|
4.73%
|
3.52%
|
56.52%
|
Announcement Date
|
30/03/17
|
30/03/18
|
29/03/19
|
30/03/20
|
29/03/21
|
28/03/22
|
|
1st Jan change
|
Capi.
|
---|
| +30.63% | 6.97Cr | | +2.99% | 9.48TCr | | -3.68% | 3.76TCr | | -9.20% | 3.33TCr | | +75.29% | 2.79TCr | | -13.42% | 1.59TCr | | -3.66% | 1.38TCr | | -12.31% | 1.15TCr | | +188.83% | 1.09TCr | | -53.94% | 927.07Cr |
Biopharmaceuticals
|